You're signed outSign in or to get full access.
Ecor1 Capital, LLC
EcoR1 Capital, LLC is a San Francisco-based hedge fund focused exclusively on biotechnology and life sciences investments. Founded in 2013, the firm manages approximately $5 billion in assets and employs around 21 staff members. EcoR1 serves institutional and accredited investors seeking dedicated exposure to the biotech sector through concentrated, research-driven public equity portfolios.
Investment Strategy
EcoR1 Capital deploys a highly focused strategy investing in publicly traded biotechnology companies, leveraging deep scientific expertise and a disciplined research process. The firm targets overlooked or misunderstood opportunities in the life sciences sector, relying on rigorous due diligence and close engagement with industry experts to identify companies with novel therapies or platforms capable of driving outsized, risk-adjusted returns. EcoR1 typically maintains a concentrated portfolio and seeks to create value by holding investments through fundamental inflection points.
Latest 13F Filing Activity
Ecor1 Capital, LLC filed their most recent 13F report on Jun 30, 2025 disclosing 36 equity positions and 1 options positions with a total 13F market value of $2B. The fund increased holdings in Iteos Therapeutics Inc., Zymeworks Inc., Tango Therapeutics Inc. among other positions. Ecor1 Capital, LLC reduced exposure to Prothena Corp. PLC, Sarepta Therapeutics Inc., Apellis Pharmaceuticals Inc. among others.
Top Holdings
Equity Positions (36)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
Z ZYME | ZYMEWORKS INC | 17.06% | $288.3M | 22,970,388 | $10.13 | $12.55 | +$82.7M |
A APLS | APELLIS PHARMACEUTICALS INC | 12.19% | $205.9M | 11,895,808 | $43.61 | $17.31 | -$54.2M |
J JAZZ | JAZZ PHARMACEUTICALS PLC | 10.72% | $181.1M | 1,706,469 | $118.51 | $106.12 | -$30.8M |
A ANAB | ANAPTYSBIO INC | 10.36% | $174.9M | 7,880,094 | $19.63 | $22.20 | +$28.4M |
C CRNX | CRINETICS PHARMACEUTICALS IN | 7.30% | $123.3M | 4,288,120 | $37.51 | $28.76 | -$20.5M |
Options Positions (1)
| Ticker | Security | Action | Type | Notional Value | Contracts | Underlying Price | Premium Paid | Change (Contracts) | Change (Value) |
|---|---|---|---|---|---|---|---|---|---|
Q QURE | UNIQURE NV | — | Call | $1.9M | 1,350 | $13.94 | $17.66 | 0 | +$450.9K |
Industry Allocation
Investment Team (9)
| Name | Role | Location | |
|---|---|---|---|
 | Principal | San Francisco, CA , United States | |
 | Principal | San Francisco, CA , United States | |
 | Analyst | San Francisco, CA , United States | |
 | Analyst | United States | |
 | Partner | San Francisco, CA , United States | |
 | Analyst | United States | |
 | Investment Analyst | San Francisco, CA , United States | |
W Whan Lee | Analyst | United States | |
 | Research Associate | San Francisco, CA , United States |
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more